23: Early hematopoietic cells, including megakaryocyte progenitors, are recovered in ALDH bright cell populations isolated by cell sorting from previously frozen umbilical cord blood  by Deibert, E. et al.
involved with tumor target recognition (Farag et al Blood, 2002). In
particular, AML and Neuroblastoma are NK sensitive pediatric
tumors. CB is limited by the absence of available donor effector
cells (NK, CTL, LAK and NKT cells) for infusion after UCBT
(Cairo et al Transfusion, 2005). We demonstrated the ability to EvE
CB in short-term culture with IL-2, IL-7, IL-12 and anti-CD3
with increased CD3-/16/56dim and bright subsets expressing
KIR3DL1, KIR2DL2, KIR2DL1/S1 and CD94/NKG2a with in-
creased NK and LAK cytotoxicity (Ayello/Cairo et al BBMT,
2006). In this study, we compared short-term culture (48 hrs) with
prolonged cultures (4-10 days) on expansion of NK cells expressing
NCR, KIR, NKG2, lytic ability and mechanisms of tumor lysis.
Rethawed CB cells were cultured 2-10 days with anti-CD3 (50
ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml)
[ABCY]. NKR expression (KIR2DS4, NKG2D, CD94, NKp46),
intracellular granzyme B and LAMP-1 receptor (CD107a) expres-
sion were determined by ﬂow cytometry. Cytotxcity of EvE effec-
tor CB cells was measured by europium release assay at 20:1 E:T
ratio with tumor targets K562 (NK), Daudi (LAK), Kasumi-1
(AML) and SYSY5Y (neuroblastoma). KIR2DS4 was signiﬁcantly
increased at day 10 vs 2 in ABCY in both CD3-/16/56bright and dim
subsets (16.9	0.4 vs 2.1	0.2% and 22.3	0.3 vs 0.9	0.2%,
p0.001, respectively). C-lectin receptor CD94/NKG2D expres-
sion was increased at day 7 vs 2 (41.4	0.43 vs 23.7	2.0%,
p0.001). NCR expression in CD3-/16/56dim NKp46 subset
was increased at day 7 vs 2 (10.1	0.06 vs 2.62	0.8, p0.001).
Granzyme B expression was increased from day 2 to 10 (25.8	1.7
vs 45.1	1.7%, p0.001). CD107a expression was signiﬁcantly
increased at day 7 vs 2 (12.9 	1.4 vs 69.3	2.2%, p0.001).
Additionally, increased cytotoxicity was demonstrated at day 7 vs 2
with tumor targets K562 (71.5	0.81 vs 53.8	3.9%, p0.001),
Daudi (63.9	0.73 vs 38	1.1%, p0.001), Kasumi-1 (56.6	0.4 vs
31.8	1.8, p0.001) and SYSY5Y (59.5	5.35 vs 32.6	4.9%,
p0.01). In summary, CB MNC may be thawed at time of trans-
plantation, recryopreserved, rethawed at a later date, expanded and
activated up to 10 days to yield viable NK subsets which appear to
be cytolytic against AML and Neuroblastoma and could be poten-
tially used as ACI post UCBT.
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EARLY HEMATOPOIETIC CELLS, INCLUDING MEGAKARYOCYTE PRO-
GENITORS, ARE RECOVERED IN ALDH BRIGHT CELL POPULATIONS
ISOLATED BY CELL SORTING FROM PREVIOUSLY FROZEN UMBILICAL
CORD BLOOD
Deibert, E.1, Gentry, T.1, Foster, S.J.1, Kurtzberg, J.2, Balber, A.E.1
1Aldagen, Inc., Durham, NC; 2Duke University Medical Center,
Durham, NC.
ALDH bright [ALDHbr] cell populations sorted from fresh um-
bilical cord blood [UCB] on the basis of their high aldehyde
dehydrogenase [ALDH] activity are known to include hematopoi-
etic progenitor cells [HPC]. However, neither the hematopoietic
potential of ALDHbr cells recovered from previously frozen UCB,
nor the ability of any ALDHbr cells to generate platelets has been
reported. We have measured hematopoietic [CFC-H] and
megakaryocytic [CFC-M] colony forming cells in ALDHbr and
ALDHdim [depleted of ALDHbr cells] populations from thawed
UCB. Cells were washed, immunomagnetically depleted of cells
expressing glycophorin A and CD14, reacted with ALDE-
FLUOR® for ﬂow cytometric detection of ALDH, and sorted to
yield ALDHbr and ALDHdim populations. ALDHbr cells com-
prised 0.38 	 0.15% [mean 	 SD] of thawed UCB cells. CD34
and CD133 cells comprised 90.9 	 3.1% and 57.7 	 9.4 % of
ALDHbr cells, respectively. CD41 and CD110 cells were 23.4	
11.7% and 1.7 	 3.4 % of the ALDHbr population, respectively.
CFC-H activity was enriched 1116-fold in the ALDHbr population
compared to the ALDHdim population [256 	 104 colonies/1000
cells vs. 0.23 	 0.33 colonies/1000 cells], and 65% of the CHC-H
were recovered in the ALDHbr population. The ratio of erythroid
to myeloid colonies generated from ALDHbr population was 3.7.
Others have shown that most ALDHdim HPCs in fresh UCB are
short term progenitors, whereas earlier long-term culture initiating
cells and cells that establish long-term grafts in NOD-SCID
mouse models are ALDHbr. Consistent with this, we found that
GEMM colonies are about ten times more frequent in ALDHbr
CHC-H [6.6 	 4.5 GEMM /1000 cells] than in ALDHdim [0.6 	
1.2 GEMM/1000 cells] cells from thawed UCB. Furthermore,
CFC-M activity was 2015-fold higher in the ALDHbr population
than the ALDHdim population [60 	 35 colonies/1000 cells vs.
0.03 	 0.02 colonies/1000 cells]. Cells giving rise to large
megakaryocyte colonies, usually considered to be CFC-M with the
most self-renewal potential, were particularly enriched in the AL-
DHbr populations; all the large colonies we detected [38.0 	17.4
large CFC-M/1000 cells] were derived from ALDHbr populations.
The rare CFC-M colonies from ALDHdim cells were small or
non-megakaryocytic. These results suggest that ALDHbr cells re-
covered from thawed, banked UCB could be used to reconstitute
erythroid and myeloid, including megakaryocytic, blood elements
after transplantation.
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PD-1 IS REQUIRED TO INDUCE PERIPHERAL CD8 T CELL TOLERANCE
IN RECIPIENTS OF ALLOGENEIC BONE MARROW TRANSPLANTATION
WITH ANTI-CD154
Haspot, F.1, Fehr, T.1, Hogan, T.1, Honjo, T.2, Sykes, M.1 1BMT/
TBRC, Massachusetts General Hospital, Harvard Medical School, Bos-
ton, MA; 2Department of Immunology and Genomic Medicine, Kyoto
University, Graduate School of Medicine, Yoshida, Kyoto, Japan.
We examined the mechanisms involved in peripheral CD8 T cell
tolerance induced by mixed chimerism achieved with non-myeloa-
blative conditioning with low-dose (3 Gy) total body irradiation
(TBI) and 2mg of anti-CD154 antibody. CD8 T cell tolerance is
CD4 dependent and is characterized by a speciﬁc anergic state
toward donor antigens prior to speciﬁc deletion of donor-reactive
cells. We tested the role of the PD-1 pathway in a model in which
only CD4 peripheral tolerance is required (i.e. TBI 3 Gy and
depleting anti-CD8 mAb Day -1, 2mg of anti-CD154 Day 0
followed by allogeneic BMT) and in a model in which both CD4
and CD8 peripheral tolerance is required (i.e. TBI 3 Gy Day -1
and 2mg of anti-CD154 followed by allogeneic BMT) for the
development of mixed chimerism. PD1-/- (C57BL/6 background)
or C57BL/6 wild-type mice received fully allogeneic bone marrow
cells (B10.A). While WT control mice showed successful mixed
chimerism induction with both regimens, the PD1-/- recipients
failed to develop mixed chimerism unless they were CD8 depleted.
These results indicate that PD1 is required for the tolerance of
peripheral donor-reactive CD8 cells but not for that of CD4 T
cells. We conﬁrmed these results using blocking anti-PD1 and
anti-PD-L1 mAb in WT B6 recipient mice. While control groups
again showed successful engraftment, recipient mice treated with
blocking anti-PD-1 and anti-PDL-1 mAb failed to develop mixed
chimerism unless they were depleted of CD8 cells. Chimeric mice
that were CD8 depleted and received PD-1 blockade accepted
donor skin grafts while rejecting third party grafts. Thus, a func-
tional PD1-PDL1 pathway is critical to achieve donor-speciﬁc
CD8 T cell tolerance in our model.
GVH/GVL
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BLOOD EOSINOPHILIA AS A MARKER OF FAVORABLE OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Aisa, Y.1, Mori, T.1, Nakazato, T.1, Shimizu, T.1, Yamazaki, R.1,
Ikeda, Y.1, Okamoto, S.1 1Keio University Hospital, Tokyo, Japan.
Eosinophilia is observed in a variety of systemic disorders includ-
ing acute and chronic graft-versus-host disease (GVHD) after
allogeneic stem cell transplantation (allo-SCT). The clinical
records of 237 adult patients who underwent allo-SCT were ret-
rospectively reviewed. Peripheral complete blood cell counts
(CBCs) had been performed at least two or three times a week until
day 100 in all cases, and white blood cell differentiation was
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